Izotropic Corp. Advances Breast Cancer Imaging with Exclusive Breast CT Technology

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) stands out as a medical device company with exclusive global rights to Breast CT technology developed at UC Davis, positioning it as a leader in breast cancer imaging innovation. The company's IzoView technology offers a proprietary alternative to traditional mammography, specifically designed for dense breast tissue imaging, addressing a significant unmet need in the market.

With regulatory alignment secured with the FDA, Izotropic is preparing for a pivotal U.S. clinical trial, marking a critical step towards bringing its technology to the forefront of breast cancer screening and diagnosis. The company's comprehensive business and financial plan supports its journey across clinical, regulatory, and commercial milestones, aiming to enhance diagnostic confidence and improve patient experience.

Izotropic's mission focuses on delivering transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. Through innovation in device architecture and image acquisition, the company is targeting the multibillion-dollar global breast imaging market with its next-generation imaging platform.

To drive engagement and investor visibility, Izotropic has launched awareness campaigns, including a dedicated website and a company podcast. These initiatives are designed to highlight the potential of Breast CT technology in revolutionizing breast cancer detection and treatment.